# US 2012/0252015 A1 · Methods and compositions for detecting genetic material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252015 A1
- Document ID: US20120252015A1
- Status: Published application
- Kind: A1
- Application number: 13/400,030
- Filed: 2012-02-17
- Published: 2012-10-04
- Earliest claimed: 2011-02-18
- Assignees: Bio-Rad Laboratories, Inc.
- Inventors: Benjamin Hindson; Serge Saxonov; Philip Belgrader; Kevin Ness; Michael Lucero; Billy Colston; Shawn Paul Hodges; Nicholas J. Heredia; Jeffrey Clark Mellen; Camille Bodley Troup; Paul Wyatt
- Web page: https://patentgrep.com/patent/US20120252015A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2521/331: Methylation site specific nuclease
- C12Q 2523/125: Bisulfite(s)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods and compositions for detecting polynucleotides in a sample and for quantifying polynucleotide load in a sample. The polynucleotides can be associated with a disease, disorder, or condition. In some applications, methylated DNA is quantified, e.g., in order to determine the load of polynucleotides in a sample. The present disclosure also provides methods and compositions for determining the load of fetal polynucleotides in a biological sample, e.g., the load of fetal polynucleotides (e.g., DNA, RNA) in maternal plasma. The present disclosure provides methods and compositions for detecting cellular processes such as cellular viability, growth rates, and infection rates. This disclosure also provides compositions and methods for detecting differences in copy number of a target polynucleotide. In some embodiments, the methods and compositions provided herein are useful for diagnosis of fetal genetic abnormalities, when the starting sample is maternal tissue (e.g., blood, plasma).

## Claims

### Claim 1

A method of detecting methylated DNA, comprising:
a. contacting a nucleic acid sample with a methylation-sensitive reagent;
b. partitioning said nucleic acid sample into a plurality of spatially-isolated partitions;
c. detecting a first locus within said nucleic acid sample, wherein said first locus is hypermethylated in fetal nucleic acid; and
d. quantifying the amount of said first locus, thereby detecting methylated nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein said spatially-isolated partitions are emulsified droplets.

### Claim 3 (depends on 2)

The method of claim 2, wherein said first locus is selected from the group consisting of: RASSF1A, CASP8, RARB, SCGB3A1, DAB2IP, PTPN6, THY1, TMEFF2, APC, and PYCARD.

### Claim 4 (depends on 1)

The method of claim 1, wherein said methylation-sensitive reagent is a methylation-sensitive enzyme.

### Claim 5 (depends on 1)

The method of claim 1, further comprising detecting a second locus within said nucleic acid sample, wherein said second locus is present in both the maternal and fetal nucleic acid and wherein said second locus is not significantly cleaved by said methylation-sensitive reagent.

### Claim 6 (depends on 1)

The method of claim 1, further comprising detecting a third locus within said nucleic acid sample, wherein said third locus is present in both the maternal and fetal nucleic acid and wherein said third locus is significantly cleaved by said methylation-sensitive reagent.

### Claim 7 (depends on 1)

The method of claim 1, further comprising amplifying a sequence associated with said first locus to produce a detectable signal.

### Claim 8 (depends on 7)

The method of claim 7, wherein said signal is a fluorescent signal.

### Claim 9

A method of quantifying methylated nucleic acid, comprising:
a. contacting a nucleic acid sample with a methylation-sensitive reagent, wherein said nucleic acid sample comprises a major population and a minor population;
b. partitioning said nucleic acid sample into a plurality of spatially-isolated partitions;
c. detecting a first quantity of a first locus within said nucleic acid sample;
d. detecting a second quantity of a second locus within said nucleic acid sample; and
e. comparing said first and second quantities, to obtain a value indicative of a percentage of methylated nucleic acid in the sample.

### Claim 10 (depends on 9)

The method of claim 9, wherein said plurality of spatially-isolated partitions are emulsified droplets.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein said major population comprises maternal DNA and said minor population comprises fetal DNA.

### Claim at position 13

-38. (canceled)

### Claim 39

A method of quantifying methylated nucleic acid, comprising:
a. splitting a nucleic acid sample into a target portion and reference portion;
b. contacting the target portion with a methylation-sensitive enzyme;
c. partitioning each of the target portion and reference portion into a plurality of spatially isolated partitions;
d. amplifying a locus within said target portion and a locus within said reference portion, wherein the amplification produces a detectable signal; and
e. measuring a ratio of detectable signals from the target and reference portions, thereby quantifying methylated nucleic acid.

### Claim 40 (depends on 39)

The method of claim 39, wherein said locus within said target portion is the same genetic locus as said locus within said reference portion.

### Claim at position 16

-42. (canceled)

### Claim 43 (depends on 39)

The method f claim 39, wherein said spatially-isolated partitions are emulsified droplets.

### Claim at position 18

-50. (canceled)

### Claim 51

A method of determining fetal sex, comprising:
a. dividing a sample of nucleic acids into a first and second subsample, wherein said sample comprises maternal and fetal nucleic acids;
b. contacting said first subsample with a methylation-sensitive enzyme;
c. partitioning each of said subsamples into a plurality of emulsified droplets;
d. amplifying a first locus within the first subsample and a second and third loci within the second subsample, wherein the amplification produces a detectable signal; and
e. computing a value reflecting both a first ratio and a second ratio, wherein said first ratio is computed using detectable signals from said first and second loci and said second ratio is computed using detectable signals from said first and third loci, thereby determining fetal sex.

### Claim 52

(canceled)

### Claim 53 (depends on 51)

The method of claim 51, wherein said second locus is hypermethylated in fetal DNA compared to maternal DNA.

### Claim 54 (depends on 53)

The method of claim 53, wherein said first ratio is positively correlated with the amount of fetal DNA in said sample.

### Claim at position 23

-60. (canceled)

### Claim 61

A method for detecting variations in a polynucleotide comprising:
a. incubating a sample with a first restriction enzyme, wherein said sample comprises: a first allele of a polynucleotide, wherein said first restriction enzyme preferentially digests a second allele of said polynucleotide over said first allele of said polynucleotide; and
b. performing digital PCR on said sample in order to detect said first allele.

### Claim 62 (depends on 61)

The method of claim 61, wherein said digital PCR is droplet digital PCR.

### Claim at position 26

-67. (canceled)

### Claim 68 (depends on 61)

The method of claim 61, wherein said detecting comprises hybridizing a first probe specific to said wild-type polynucleotide and a second probe specific to said mutant polynucleotide.

### Claim at position 28

-71. (canceled)

### Claim 72

A method for detecting variations in a polynucleotide comprising:
a. incubating a sample with a first restriction enzyme, wherein said sample comprises:
i. a wild-type polynucleotide; and
ii. a mutant polynucleotide that is a mutant form of said wild-type polynucleotide, wherein the number of copies of said mutant polynucleotide is less than 0.1% of the total copies of polynucleotides in the sample; and
b. performing digital PCR on said sample in order to detect said mutant polynucleotide.

### Claim 73 (depends on 72)

The method of claim 72, wherein said mutant polynucleotide is detected with an accuracy of greater than 60%.

### Claim 74

A population of at least 5,000 emulsified droplets comprising polynucleotides obtained from a mixed sample of DNA wherein said mixed sample of DNA comprises:
a. a population of DNA comprising a first allele of a polynucleotide; and
b. a population comprising a second allele of a polynucleotide; and
wherein greater than 50% of said emulsified droplets comprise said first allele and wherein each of said emulsified droplets comprises on average one copy of said said first allele.

### Claim 75

A method for detecting a target polynucleotide with an allele of interest, the method comprising:
a. incubating a sample with an endonuclease that recognizes and cleaves non-perfectly matched double stranded DNA, wherein said sample comprises:
i. a background polynucleotide comprising a sequence of a first allele of a genetic marker,
ii. a target polynucleotide comprising a sequence of a second allele of said genetic marker, and
iii. a probe that is perfectly complementary to said sequence of said second allele of said genetic marker; and
b. detecting said target polynucleotide by subjecting said sample to digital PCR.

### Claim 76 (depends on 75)

The method of claim 75, wherein said detecting step comprises performing an assay with a detection probe that is perfectly complementary to at least a portion of said target polynucleotide.

### Claim 77 (depends on 76)

The method of claim 76, wherein said detection probe comprises an LNA modification.

### Claim at position 35

-80. (canceled)

### Claim 81

A method for measuring the growth rate of a cellular population comprising:
a. removing a first portion from said cellular population;
b. measuring a quantity of polynucleotides within said first portion of said cellular population using digital PCR;
c. after said removing of step a, removing a second portion from said cellular population;
d. measuring a quantity of polynucleotides within said second cellular population using digital PCR; and
e. comparing said quantity of polynucleotides obtained in step b with said quantity of polynucleotides obtained in step d.

### Claim 82 (depends on 81)

The method of claim 81, wherein said digital PCR of step b is droplet digital PCR.

### Claim 83 (depends on 81)

The method of claim 81, wherein said digital PCR of step d is droplet digital PCR.

### Claim at position 39

-89. (canceled)
